Breast Cancer Clinical Trial
Official title:
Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma
Objectives:
- To find out the maximum tolerated dose of the GI-6207 vaccine (the highest dose that
does not cause unacceptable side effects), and to evaluate any side effects.
- To see if GI-6207 has any effect on patients tumors.
- To learn how the vaccine causes immune responses against the cancer.
Eligibility:
- Patients 18 years of age and older who have been diagnosed with a cancer that has not
responded to standard treatments. Patients must not be allergic to yeast or yeast
products.
Design:
- Initial physical examination, blood and tissue sampling, computed tomography (CT) scan,
and skin test to determine eligibility for the procedure.
- Treatment with GI-6027 in seven 14-day cycles as follows:
- Vaccine administered on days 1, 15, 29, 43, 57, 71, and 85.
- Vaccine given at four sites around the body: right and left chest area below the armpit,
and right and left upper thigh in the pelvic region. (These areas drain into parts of
your body that contain large numbers of lymph nodes. The lymph nodes contain immune
cells that may be activated by the vaccine to target cancer cells.)
- Clinic visits for physical examinations to check vital signs, take additional blood and
urine samples, and perform other tests needed for the study.
- After day 85 (about 3 months), patients will continue to receive vaccine monthly (or
every 28 days) as long as the vaccine is not producing harmful effects or side effects
and the cancer is either stable or reducing. Patients who do well on the vaccine may
continue to receive it for as long as it is available.
Background:
Carcinoembryonic antigen (CEA) is overexpressed in multiple adenocarcinomas.
Previous clinical studies utilizing CEA-based vaccine therapy have demonstrated safety,
T-cell immune responses against CEA, and preliminary evidence of clinical benefit.
Preclinical studies have shown that Saccharomyces-CEA (yeast-CEA) can induce a strong immune
response to CEA as well as therapeutic antitumor responses in a CEA-transgenic host.
Previous and ongoing clinical studies utilizing whole, heat-killed recombinant Saccharomyces
cerevisiae yeast genetically modified to express mutated Ras (GI-4000) or hepatitis C
(GI-5005) proteins demonstrated this vaccine vehicle to be well tolerated, with no
product-related serious adverse events in >200 treated subjects.
Objectives:
Primary
-To determine the safety and tolerability of escalating doses of a heat-killed yeast-based
vaccine that targets tumors that express CEA.
Secondary
- To evaluate CD4 and CD8 immunologic response as measured by an increase in CEA-specific
T cells measured by ELISPOT in HLA-A2, -A3 and -A24(+) patients, and proliferation in
response to CEA protein.
- To evaluate evidence of clinical benefit, such as progression-free survival, RECIST
criteria, reduction in serum markers, and/or reduction in circulating tumor cells.
Eligibility: (dose escalation phase)
Must have metastatic cancer that is CEA-positive (either a CEA serum level > 5 ng/mL or a
tumor that stains positive for CEA in > 20% of a tumor block).
Must have completed or had disease progression on at least one prior line of
disease-appropriate therapy, or not be a candidate for therapy of proven efficacy for their
disease.
Must be ECOG Performance Status 0 2.
Should have no autoimmune diseases; no evidence of immune dysfunction; no serious
intercurrent medical illness;
No untreated brain metastasis (or local treatment of brain metastases within the last 6
months)
Any hypersensitivity reaction to yeast-based products.
Eligibility: (extension phase: 10 additional patients at highest tested dose/MTD)
Same as for the dose escalation phase with the following exceptions:
- Patients must be HLA-A2, -A3, or -A24(+) for immunologic monitoring
- ECOG PS = 0 1
Design:
This is an open label, phase I trial with sequential cohorts of patients (3-6 patients per
dose cohort) with dose escalation of heat-killed GI-6207 vaccine (see statistical analysis
section).
GI 6207 vaccine will be administered subcutaneously at 4 sites biweekly for 7 visits (days 1,
15, 29, 43, 57, 71, 85), then monthly until patients meet off-study criteria.
All patients on a given dose level will have completed 1 month on-study before enrollment can
begin on the next dose level or on the extension phase (see statistical analysis section).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |